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Abstract
Background: Trends in the use of  antipsychotics and alpha agonists for the treatment of  tic disorders in Canadian children, and how closely these trends align 
with evidence-based guidelines on the pharmacotherapy of  tic disorders, have not been explored.
Methods: IQVIA’s Canadian Disease and Therapeutic Index, a survey-based data set, was used to identify prescription patterns by physicians. Respondents 
recorded all patient visits during a 48-hour period in each quarter of  the year, including patient age, gender, drug recommendation and therapeutic indication. 
Recommendations for alpha agonists and antipsychotics from 2012 to 2016 were analysed for children and adolescents with tic disorders.
Results: Risperidone and clonidine were the most commonly recommended medications for tic disorders over the study period, with 36,868 and 35,500 recom-
mendations in 2016, respectively. Recommendations for clonidine increased over the study period, whereas those for risperidone decreased. Guanfacine (approved 
in Canada in 2013) was used less frequently than clonidine. Clonidine was more frequently recommended than antipsychotics in children younger than 6, in whom 
antipsychotic recommendations were uncommon. Aripiprazole was the second most commonly recommended antipsychotic for tic disorders, with 22,892 recom-
mendations in 2016. Of  the first-generation antipsychotics, pimozide was most commonly recommended (11,334 recommendations in 2016); haloperidol was 
infrequently recommended.
Discussion: The trends observed are in line with guideline recommendations reflected in the decreasing use of  risperidone, and the growing use of  clonidine and 
guanfacine. The growing use of  aripiprazole is likely due to emerging evidence from clinical trials supporting its efficacy for tics. Recommendations for pimozide 
and haloperidol were limited, likely due to the greater adverse effects associated with these medications.
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Introduction
Tic disorders have been conceptualised as hyperkinetic movement 
disorders, manifesting as brief  and intermittent movements (motor tics) 
or sounds (phonic tics), and further characterised by their highly repeti-
tive nature and waxing-and-waning course.1 Motor tics are typically 
sudden and may appear as simple motor tics (e.g., blinking, shoul-
der-shrugging and facial grimacing), or as complex motor tics resem-
bling gestures or other elements of  normal behaviour. Phonic tics 
include sniffing, clearing of  the throat, grunting, chirping or more com-
plex vocalisations such as words or phrases. Frequently, a premonitory 
sensation or urge heralds the appearance of  a tic.1,2 The most common 
cause of  tics in childhood is Tourette syndrome (TS), which is character-
ised by both motor and phonic tics and is often accompanied by psychi-
atric comorbidities including attention deficit hyperactivity disorder 
(ADHD) or obsessive-compulsive disorder (OCD). The Canadian prev-
alence estimate of  diagnosed TS in youth is 6.03 per 1,000 in males and 
0.48 per 1,000 in females.3
Medications and behavioural interventions comprise the main treat-
ments for tics.4–6 However, tic severity and the degree to which patients 
suffer physical, emotional or social distress are often such that no treat-
ment is necessary.4,7 Oral medications for tics include alpha 2- adrenergic 
agonists, antipsychotics, topiramate and tetrabenazine.4 A behavioural 
intervention for which there is strong evidence is Comprehensive 
Behavioural Interventions for Tics (CBIT), which includes habit rever-
sal therapy (HRT) as its primary component.8 This is considered the 
first-line treatment for tics in patients over the age of  9 and entails 
self-monitoring of  tics and their premonitory urges, with the goal of  
learning to perform a counteracting behaviour that is incompatible with 
the tic.8 After CBIT/HRT, medications form the second tier of  treat-
ment for tics, based on collaborative decision-making with parents.7 
Alpha agonists, such as clonidine and guanfacine, have been identified 
by Roessner et al. as commonly prescribed among European experts in 
TS, with clonidine as the second most commonly prescribed medication 
for tics according to their survey.9 Canadian guidelines put forward a 
strong recommendation for alpha agonists, as a result of  moderately 
strong evidence of  efficacy coupled with their favourable side effect pro-
file relative to antipsychotic medications.8 Antipsychotic medications are 
well studied and have been widely used in the treatment of  tics and 
include both first-generation agents, such as pimozide and haloperidol, 
and second-generation agents, such as risperidone and aripiprazole.4 
The efficacy of  pimozide and haloperidol in the treatment of  tics is well 
established, as is their association with metabolic side effects, drug-in-
duced movement disorders and QTc prolongation.9,10 Similar evidence 
exists supporting the efficacy of  risperidone and aripiprazole, as well as 
concerns regarding side effects.8–10 Although high-quality evidence sup-
ports the efficacy of  several antipsychotics, Canadian guideline recom-
mendations for these are weak owing to unfavourable side effect 
profile.4,8 Although these data are generally elusive, it is vital to study 
trends in prescribing for paediatric tic disorders and to investigate 
whether or not such trends fall in line with evidence-based guidelines.
As noted above, in the North American context, Pringsheim et al. 
evaluated the evidence pertaining to several therapies for tics and made 
strong recommendations for clonidine and guanfacine for the treatment 
of  tics in children, but weak recommendations for many antipsychotics 
due to high rates of  side effects (including metabolic effects such as 
weight gain), despite the strong evidence supporting their efficacy.8 An 
important distinction thus emerges between evidence of  efficacy and 
strength of  recommendation for a given treatment. Pringsheim et al. 
used the Grading of  Recommendations Assessment, Development and 
Evaluation (GRADE) system, in which there is a separation between 
quality of  evidence and strength of  recommendations.11 Based on risk 
of  bias, the quality of  evidence in the GRADE system may be rated as 
high, moderate, low or very low. Two grades of  recommendation – 
strong and weak – give an indication of  when the benefits of  a treatment 
clearly outweigh the risk of  side effects. Acknowledgment of  values, 
preferences and circumstances that may affect recommendations is part 
of  the GRADE system and figures largely in the case of  weakly recom-
mended treatments. That is to say, a treatment may merit a strong rec-
ommendation when it can be recommended to most patients in most 
circumstances. In the case of  a weakly recommended treatment, the 
balance of  risks and benefits is less favourable, and therefore the best 
course of  action depends strongly on patient values, preferences and 
circumstances. A simultaneous appreciation of  quality of  evidence and 
strength of  recommendation thus allows for a medication supported by 
high-quality evidence to nevertheless receive a weak recommendation.
Elucidating trends in prescribing may be approached through sur-
veys of  patients and physicians.5,9,10 On a larger scale, database 
approaches may shed light on prescribing trends in Canada. This is an 
established approach, the utility of  which was demonstrated using the 
Canadian Disease and Therapeutic Index (CDTI) in the study of  anti-
psychotic use in Canada.12 Similarly, private vendors of  physician pre-
scribing data have been leveraged for pharmacoepidemiologic study, as 
one group showed in their research on the increasing use of  selective 
serotonin reuptake inhibitors in children.13 In the present study, data 
were drawn from the CDTI and used to infer prescribing trends for 
children with tic disorders, attending to drug class, molecule and patient 
age. These were compared with current guidelines for the treatment of  
tic disorders in children. The aim was to gauge how closely the trends 
approximate existing guidelines.
Methods
IQVIA’s CDTI was used as a proxy measure of  prescriptions for chil-
dren with tic disorders. CDTI is a survey-based data set that collects 
treatment data from a sample of  office-based physicians in Canada and 
allows for analyses to identify pharmacoepidemiologic patterns by drug, 
indication, patient demographics and physician specialty. A random 
sample of  physicians, stratified by region in Canada and by office-based 
specialty, is requested to complete a survey of  patients they have seen 
during the reporting period, and capturing information on patient 
demographics, diagnosis and prescribing decisions, among other infor-
mation. All major office-based specialties are represented, with repre-
sentation based on proportionality. Some specialties with very few 
physicians are over-sampled to allow for greater reliability in these areas. 
A minimum of  85% of  reporting physicians in a current period are 
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maintained from the previous reporting period. Statistical weighting, 
stratified by region and specialty, of  the reported prescribing from the 
sample physicians to the universe of  physicians is conducted to derive 
national projections. Projection factors are adjusted to compensate for 
the over-sampling. CDTI is an ideal source for this type of  study as 
compared to administrative prescription records, as the latter are typi-
cally collected in specific Canadian populations (e.g., those covered by 
publicly or privately funded drug plans) and prescribed certain drugs 
(covered by those plans), often without information about indication or 
prescribing intent.
Participating physicians complete an anonymised record of  all 
patient visits during a 48-hour period in each quarter of  the year, 
including patient age, gender, drug recommendation (prescribed drug) 
and reason for recommendation (therapeutic indication). Rate of  pre-
scription purchases was not recorded in this database. Informed consent 
was not required as no personal identifying information was collected.
The data analysed for this study reflected the time period from 2012 
to 2016, or from 2010 to 2016 in the specific case of  antipsychotic med-
ications, and were reviewed as a spreadsheet in Microsoft Excel (2017; 
Redmond, WA, USA). Drug recommendation totals were taken for all 
column entries designated as “Tic Disorder”. The medication class and 
molecules analysed for all tic disorder entries included the alpha ago-
nists clonidine and guanfacine; the antipsychotics class represented as 
first-generation antipsychotics (chlorpromazine, chlorprothixene, dro-
peridol, flupentixol, fluphenazine, fluspirilene, haloperidol, loxapine, 
mesoridazine, methotrimeprazine, periciazine, perphenazine, pimozide, 
piperacetazine, pipotiazine, prochlorperazine, promazine, thio-
prapazate, thioproperazine, thioridazine, trifluoperazine and zuclopen-
thixol); and the antipsychotics class represented as second-generation 
antipsychotics (aripiprazole, asenapine, clozapine, lurasidone, olanzap-
ine, paliperidone, quetiapine, risperidone and ziprasidone). The CDTI 
allowed for the drug recommendation totals to be further subdivided by 
patient age into three groups: those aged 1–6 years, 7–12 years and 
13–18 years. Similar age categories have been used in previous stud-
ies.14–16 Bachmann et al. have shown that psychopharmacological treat-
ment of  tics is highest in teenaged patients.17 Overall, the focus of  the 
present study was on drug recommendations for the specific indication 
of  tic disorders, in patients belonging to the three age categories listed 
above.
The data pertaining to physician specialty list their medication rec-
ommendations by medication class/molecule but not by indication. 
Therefore, the analyses in the current study, which are specific to recom-
mendations for the treatment of  tic disorders, capture recommenda-
tions made by general practitioners, neurologists, psychiatrists and 
paediatricians. Furthermore, the indication “Tic Disorder”, as listed in 
the CDTI, is not subdivided further into the specific diagnosis of  TS.
Results
The overall trends revealed by the CDTI were for greater recom-
mendations for antipsychotics than for alpha agonists, with a relatively 
small decrease in recommendation totals over time for antipsychotics, 
and a steady increase in the number of  recommendations for alpha ago-
nists. In the case of  antipsychotic medications, recommendation totals 
were 85,010 in 2010 and fell to 71,094 in 2016. The alpha agonists 
clonidine and guanfacine were collectively recommended in increasing 
amounts, from 17,850 in 2012 (reflecting clonidine alone) to 45,752 in 
2016 (reflecting both clonidine and guanfacine).
Medications in the alpha agonist class
Table 1 summarises the recommendations for medications in this 
class by year and age category. Combining all three age categories, rec-
ommendations for clonidine were higher than guanfacine. Clonidine 
was recommended in increasing amounts to patients in all three age 
categories. Recommendations for clonidine were consistent and grew 
steadily, with totals of  17,850 in 2012 rising to 35,550 in 2016. The 
trend for growing recommendations for clonidine was present across the 
three age groups from 2012 to 2016, with a greater-than-threefold 
increase in those aged 1–6, a nearly one-and-a-half-fold increase in 
those aged 7–12 and nearly doubling in those aged 13–18 years.
The trend of  increasing recommendations for guanfacine was noted 
in two age categories only – in those aged 7–12 and 13–18 years – 
whereas patients aged 1–6 years contributed no data in terms of  
 guanfacine recommendations. In patients aged 7–12, guanfacine 
Table 1. Alpha Agonist Medications by Drug, Year and Patient Age
Medication 2012 2013 2014 2015 2016
Clonidine 1–6 years – 2,430 6,820 4,045 8,416
Clonidine 7–12 years 12,320 13,420 6,160 4,182 16,831
Clonidine 13–18 years 5,530 5,870 5,100 16,385 10,303
Clonidine TOTAL 17,850 21,720 18,080 24,612 35,550
Guanfacine 1–6 years – – – – –
Guanfacine 7–12 years _ _ 2,530 _ 10,202
Guanfacine 13–18 years _ _ 5,490 28,004 _
Guanfacine TOTAL 8,020 28,004 10,202
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recommendation totals increased roughly fourfold when comparing 
2016 to 2014. Similarly, amongst patients aged 13–18, guanfacine 
 recommendation totals increased by roughly a factor of  5 from 2014 
to 2015.
Medications in the antipsychotic class
Table 2 summarises the recommendations for medications in this 
class by year and age category. Medications in the antipsychotic class, 
including first-generation (haloperidol and pimozide) and second- 
generation (aripiprazole, olanzapine, quetiapine and risperidone) 
agents, have collectively been recommended for tic disorders in children 
in generally larger numbers than medications in the alpha agonist class. 
The total number of  recommendations for children with tic disorders 
for all these agents combined was 85,010 in 2010 and showed a net 
decrease to 71,094 in 2016. Second-generation antipsychotics were gen-
erally more prescribed than first-generation antipsychotics. Risperidone 
remained the most highly recommended antipsychotic medication, 
followed by aripiprazole, pimozide and quetiapine. Haloperidol and 
olanzapine were recommended infrequently. The overall trend for anti-
psychotic recommendations likely reflects an initially higher number of  
recommendations for risperidone, which then decreased over time but 
were partially offset by markedly increasing aripiprazole recommenda-
tions and a modest increase in quetiapine recommendations.
Discussion
In this study, the CDTI was used to investigate trends in prescribing 
for tic disorders in children, from 2010 to 2016, with the aim of  further 
studying how closely the trends approximate evidence-based guidelines 
for treatment of  tic disorders in children. Overall, the data show an 
increase in recommendations for alpha 2-adrenergic agonist medica-
tions, an increase in recommendations for aripiprazole and a decrease 
in those for risperidone. These trends roughly fall within evidence-based 
guidelines for the treatment of  tic disorders in children. Moreover, they 
are similar to prescribing trends in parts of  Europe.
Table 2. Antipsychotic Medications by Drug, Year and Patient Age
Medication 2010 2011 2012 2013 2014 2015 2016
Pimozide 1–6 years – – – – – – 5,811
Pimozide 7–12 years 12,440 6,250 2,914 3,833 – 3,313 5,523
Pimozide 13–18 years _ 3,220 6,172 7,052 11,372 6,730 –
Pimozide TOTAL 12,440 9,470 9,086 10,885 11,372 10,043 11,334
Haloperidol 1–6 years - - - - - - -
Haloperidol 7–12 years – – – – – 5,848 –
Haloperidol 13–18 years - - - - - - -
Haloperidol TOTAL - - - - - 5,848 -
Aripiprazole 1–6 years - - - - - - -
Aripiprazole 7–12 years – – 3,059 7,666 6,534 10,166 –
Aripiprazole 13–18 years - 3,140 18,172 7,501 7,578 3,370 22,892
Aripiprazole TOTAL 3,140 21,231 15,167 14,112 13,536 22,892
Risperidone 1–6 years - - - - - - 3,313
Risperidone 7–12 years 27,870 27,360 17,627 13,470 7,665 15,845 26,382
Risperidone 13–18 years 35,670 31,770 5,827 _ 10,144 9,218 10,486
Risperidone TOTAL 63,540 59,130 23,454 13,470 17,809 25,063 36,868
Quetiapine 1–6 years - - - - - - -
Quetiapine 7–12 years 3,090 – – – – – –
Quetiapine 13–18 years 2,970 3,260 6,118 – 7,741 – –
Quetiapine TOTAL 6,060 3,260 6,118 – 7,741 - -
Olanzapine 1–6 years - - - - - - -
Olanzapine 7–12 years 2,970 – – – – – –
Olanzapine 13–18 years - - - - - - -
Olanzapine TOTAL 2,970 - - - - - -
Note: The hyphen and endash are used to signify that there were no recorded recommendations for that drug in that year for that age group.
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Using different approaches, a number of  studies have provided 
insights regarding the effectiveness of  various medications for tics, rec-
ommendations for their use and prescription trends. Farag et al. retro-
spectively studied serial drug usage to gain insights into drug effectiveness, 
thus providing some evidence on the prescribing trends in the authors’ 
local context in London, UK.10 Prescribing trends were elucidated by 
studying the common clinical practice of  several physicians: serial phar-
macotherapy (trying reasonable options until finding an effective medi-
cation for treatment of  tics). Across a 10-year study period, prescribing 
behaviours were investigated in terms of  the outcome of  serial pharma-
cotherapy. These outcomes were categorised as follows: successful fol-
low-up on last drug used for ≥5 months (a proxy measure for drug 
success), discharge from clinic on the last drug tried, last drug discontin-
ued with no further switch to a different drug or insufficient follow-up. 
Farag et al. found that the most commonly prescribed medications for 
tics were aripiprazole (64%), clonidine (40%), risperidone (30%) and 
sulpiride (29%).10
Roessner et al. provided evidence-based recommendations for the 
treatment of  tics, arguing that the best evidence arising from ran-
domised controlled trials (RCTs) is for the typical antipsychotics halo-
peridol and pimozide, with some indications that pimozide may be 
more effective and may have a more favourable adverse reaction profile 
than haloperidol aside from its potential cardiac effects.9 For atypical 
antipsychotics, Roessner et al. argued that the best evidence was avail-
able for risperidone.9 The authors further noted that in German-
speaking nations, benzamides (e.g., tiapride and sulpiride) are commonly 
used as first-line agents.9 The benzamides are not available for use in 
Canada.
Roessner et al. collected questionnaire data from members of  the 
European Society for the Study of  Tourette Syndrome (ESSTS) regard-
ing their choices for first-, second- and third-choice, and subsequent 
choices in the treatment of  tics, rating each first-choice agent with four 
points, a second-choice agent with three points, a third-choice agent 
with two points and additional agents with one point.9 Most support 
from experts in the ESSTS was provided for risperidone, with consider-
able support for clonidine, aripiprazole and pimozide as well.9 Based on 
the available evidence, experience with the drug and experts’ prefer-
ence, risperidone was recommended as the first choice by Roessner 
et al.9 These results are also consistent with those yielded by Rickards 
et al., in which 44 members of  the ESSTS actively prescribing for pae-
diatric and/or adult TS responded to a survey, showing that risperidone 
was most commonly prescribed for the treatment of  tics.18
Hollis et al. combined a systematic review with meta-analyses of  
pharmacological, behavioural and physical treatments for children and 
youth with TS.5 An online national survey of  patients and families in the 
UK found that the most commonly used medications were risperidone, 
clonidine and aripiprazole.5 Hollis et al. reported that, at the time of  
their study, antipsychotics and alpha 2-adrenergic agonists were the only 
classes with clear RCT-based evidence supporting their short-term 
effectiveness in the treatment of  tics.5 The authors also argued that 
 aripiprazole may be equally effective when compared to other 
 antipsychotics.5 Hollis et al. noted relatively weak RCT evidence for 
topiramate, metoclopramide and desipramine, with recommendations 
for their use further mitigated by their side effects.5
As the CDTI data pertain to Canada, it is prudent to consider 
Canadian guidelines offered by Pringsheim et al.8 These may have con-
tributed to the trends revealed by the CDTI, as the authors made strong 
recommendations for guanfacine and clonidine, both of  which were 
recommended in increasing amounts in the CDTI. The growing num-
ber of  recommendations for clonidine may be interpreted as an encour-
aging sign that prescribing trends fall in line with the agents for which 
there is a lower risk of  harm.
However, some concern may be raised regarding risperidone, as the 
number of  recommendations for this medication was more variable. 
Data from the CDTI show decreasing recommendations for older 
patients aged 13–18 years, but not the same lasting decrease in younger 
patients aged 7–12. Additionally, the CDTI data show an increase in 
aripiprazole. Returning to Canadian guidelines, Pringsheim et al. 
advised cautious use of  antipsychotics, in light of  the rate and type of  
side effects.8 While the efficacy of  haloperidol, pimozide and risperi-
done is supported by high-quality evidence, they were weakly recom-
mended by Pringsheim et al., given their potential for extrapyramidal, 
metabolic and hormonal side effects, which arguably limit their use to 
patients in whom symptom severity may justify these risks.8 
Correspondingly, the CDTI data suggest a degree of  caution taken by 
prescribers, given the decreasing number of  recommendations for 
risperidone. Moreover, the relatively modest recommendations for other 
antipsychotics suggest discretion in the use of  these agents. However, the 
increase in recommendations for aripiprazole is notable in this regard, 
given the low quality of  evidence supporting its efficacy and the weak 
recommendation for treating tics at the time the Canadian guidelines 
were published in 2012.8 It is notable that the weak recommendation 
was based on adverse effects and was thus independent of  evidence of  
efficacy. Since that time, two RCTs of  aripiprazole versus placebo in 
children and adolescents with TS have been performed. Both of  these 
trials demonstrated a significant and clinically meaningful improvement 
in tics with aripiprazole compared to placebo, although metabolic and 
extrapyramidal side effects were reported. Aripiprazole was approved 
by the US Food and Drug Administration for the treatment of  tics in TS 
in 2016.19,20 The increase in the use of  aripiprazole from 2012 to 2016 
is therefore likely due to the publication of  these two positive clinical 
trials, the first of  which was published in 2013, and positive clinical 
experience with the medication.
While the CDTI data may suggest adherence to Canadian guide-
lines, the influence of  guidelines originating elsewhere merits 
consideration.
As the current study aimed to elucidate trends in drug recommenda-
tions, the concept of  adherence to guidelines deserves special attention, 
as more than just evidence factors into clinical decision-making. In addi-
tion to clinical evidence and physician knowledge, it has been shown 
that patient characteristics and values, as well as those of  the patient’s 
parents, affect clinical decision-making.21 These additional factors may 
therefore affect the Canadian trends for drug recommendations for chil-
dren with tic disorders. Medication side effects in particular may also 
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influence recommendation trends, the efficacy of  the medications not-
withstanding. In a prospective longitudinal study of  antipsychotic use in 
children, Pringsheim et al. found that metabolic side effects were com-
mon, with 26% showing undesirable increases in the body mass index 
(BMI) percentile, shifting from a healthy weight to the overweight or 
obese categories.22 The authors also demonstrated a high rate of  extra-
pyramidal side effects in children taking newer antipsychotics, with 35% 
having detectable abnormalities, contrary to widely held beliefs regard-
ing expected low rates of  such side effects in those taking newer 
antipsychotics.22
The tolerability and side effect profile of  alpha agonists warrant 
close attention, given the impact side effects arguably have on medica-
tion use and medication recommendation. In their RCT studying the 
treatment of  ADHD with comorbid TS, the Tourette’s Syndrome 
Study Group reported sedation as a common side effect of  clonidine, 
with 28% reporting moderate to severe sedation.23 Joo and Kim studied 
the tolerability of  an extended release formulation of  clonidine as a 
treatment of  ADHD and/or TS, finding sedation to be the most com-
mon adverse effect, reported in 31% of  patients.24 This was followed by 
dizziness (17.2%), and then fatigue, insomnia, night terrors, hypoten-
sion, nausea, chest discomfort, headache and aggravation of  tics, all of  
which affected less than 4% of  patients.24 In a study by Cavanna et al. 
of  the tolerability of  clonidine in adults with TS, 47.2% reported side 
effects, although in most cases these were mild and occurred with higher 
starting doses, with sedation and headache being the most commonly 
reported.25 These findings are by and large consistent with the strong 
recommendation for alpha agonists received in Canadian guidelines, 
when compared to the side effect profile of  first- and second-generation 
antipsychotic medications.
Certain limitations may have affected the current study. For the treat-
ment of  tic disorders in children, it must be noted that strong evidence 
exists for CBIT, which includes HRT.5,8,26,27 It is unclear how many 
patients in the CDTI were receiving CBIT, and so it is unclear how 
trends revealed in the CDTI may reflect adherence to guidelines, with-
out data pertaining to the adoption and recommendation of  CBIT and 
HRT. The CDTI data reflect reporting from a 48-hour period during 
each quarter, which may or may not be representative of  trends year-
round. The projected recommendation totals also introduce variability, 
both within and between physicians, perhaps failing to accurately cap-
ture the number of  medication recommendations for tic disorders 
between the reporting periods. The total number of  medication recom-
mendations does not show what proportion of  patients with tic disor-
ders are offered specific medications. It is also unknown if  drug selection 
was influenced by the presence of  particular comorbidities, or by tic 
severity or prior drug responsiveness. Whether or not drug recommen-
dations varied by physician training, specialisation or experience is also 
unknown based on the CDTI data. Assuming the diagnosis of  tic disor-
der was rendered accurately, there are several aetiologies for tics, and 
this is not captured by the CDTI data. However, this may have little 
impact, as the approach to pharmacotherapy is based on tic severity and 
not aetiology. Taken together, the above may cast some doubt on the 
validity of  medication recommendations as a measure of  adherence to 
guidelines. Similarly, as tic disorders are uncommon, and not all cases 
are treated with pharmacotherapy, there is uncertainty regarding 
how accurately the projected drug recommendation totals reflect the 
actual treatment of  patients, and thus how closely these align with 
 evidence-based guidelines. Finally, medication recommendations are 
not a direct measure of  dispensed medications, and therefore trends 
in  recommendations may not precisely reflect trends in the use of  
medications.
Despite the caveats inherent to this study, the use of  databases to infer 
trends is becoming increasingly well established.13,28,29 There is arguably 
a reciprocal relationship between the use of  databases to infer adherence 
to guidelines and to improve data collection to develop or update guide-
lines. Oyinlola et al. investigated whether “real world evidence”, as 
reflected in large databases, influenced medical practice in the UK in 12 
disease areas.30 The authors found an increasing trend in the use of  “big 
data” extracted from databases to update clinical practice.30 A reasonable 
counterargument against the usefulness of  databases is that an under-
standing of  how drug recommendations evolve may be better achieved 
by following prescriptions written by the same physicians. A longitudinal 
review of  records and prescription histories could therefore clarify 
whether recommendations represent new prescriptions or prescription 
renewals, confirm the accuracy of  diagnoses, establish tic severity and 
comorbidities, and reveal the sequence of  drug recommendations and 
the rationale underlying recommendations, such as newly published evi-
dence. While these points may weaken the validity of  databases for eval-
uating trends, in the case of  the CDTI, the sample of  652 physicians for 
this study remained fairly constant over the reporting period, with more 
than 85% of  the sample retained from one year to the next. Furthermore, 
an advantage of  using the CDTI is that it provides population-based data 
on prescribing trends, rather than those within a single practice.
In summary, medication recommendation trends in Canada for chil-
dren with tic disorders are consistent with evidence-based guidelines, 
with reasonable projections for increases in the use of  alpha 2-adrener-
gic agonists. Future studies may focus on how databases such as the 
CDTI may be applied as a tool not only for ongoing monitoring but also 
for physician education to help improve understanding of  healthcare 
delivery and inform physician education.13,28–32
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